Lipocine (LPCN) Profit After Tax (2011 - 2025)

Lipocine (LPCN) has 15 years of Profit After Tax data on file, last reported at -$3.2 million in Q3 2025.

• Quarterly Profit After Tax fell 35.21% year-over-year to -$3.2 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was -$5.5 million (down 31.29% YoY) and the FY2024 annual result came in at $10231.0, up 100.06% from the prior year.
• Profit After Tax declined to -$3.2 million in Q3 2025, from -$2.2 million in the prior quarter.
• In the past five years, Profit After Tax ranged from a high of $12.6 million in Q4 2021 to a low of -$6.8 million in Q2 2021.
• A 5-year average of -$1.9 million and a median of -$2.7 million in 2022 frame the typical range for Profit After Tax.
• Annual changes were most pronounced in 2021 — Profit After Tax surged 379.51% — and 2025, when it slumped 152.58%.
• Tracing LPCN's Profit After Tax over 5 years: stood at $12.6 million in 2021, then plunged by 117.96% to -$2.3 million in 2022, then dropped by 1.35% to -$2.3 million in 2023, then surged by 178.34% to $1.8 million in 2024, then plunged by 277.28% to -$3.2 million in 2025.
• The last three Profit After Tax figures came in at -$3.2 million (Q3 2025), -$2.2 million (Q2 2025), and -$1.9 million (Q1 2025), per Business Quant data.